Therapeutic siRNA targeting endothelial KDR decreases portosystemic collateralization in portal hypertension.

ABSTRACT: Development of portosystemic collateral vessels and gastroesophageal varices is responsible for the most serious clinical consequences of portal hypertension, but effective clinical therapies are limited. Here we developed and investigated the therapeutic potential of an innovative liposomally-formulated short-interfering RNA (siRNA) technology based on clinical stage components, capable to attenuate production of the endothelial kinase insert domain receptor (KDR), which controls portosystemic collateralization and contributes to disease progression and aggravation. These siRNAs were first validated in vitro, and then, their therapeutic potential on portosystemic collateralization and pathological angiogenesis was tested in vivo in mouse models of portal hypertension (portal vein-ligation

SUBMITTER: Gallego J 

PROVIDER: S-EPMC5665956 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature